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Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in
women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex
virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs
frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an
initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes
simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some speciﬁc cases.
Thepurposeofthispaperistoproviderecommendationsonmanagementofherpessimplexinfectionsinpregnancyandstrategies
to prevent transmission from mother to fetus.
1.Introduction
Herpes simplex virus (HSV) is an ubiquitous, enveloped,
and doublestranded DNA virus, belonging to the family of
Herpesviridae transmitted across mucosal membranes and
nonintact skin, that migrate to nerve tissues, where they per-
sist in a latent state. HSV-1 predominates in orofacial lesions,
and it is typically found in the trigeminal ganglia, whereas
HSV-2 is most commonly found in the lumbosacral ganglia
[1]. Nevertheless these viruses can infect both orofacial areas
and the genital tract. In some developed countries type 1 has
recently emerged as the prominent causative agent in genital
lesions. Changes in sexual behaviours of young adults may
partly explain its higher incidence [2, 3].
A ﬁrst primary infection develops when a susceptible
person (lacking of preexisting HSV-1 and HSV-2 antibodies)
is exposed to HSV.
Indeed, a ﬁrst nonprimary episode occurs when a person
with preexisting HSV antibodies (against type 1 or 2) expe-
riences a ﬁrst episode with the opposite HSV type.
Recurrent infection occurs in a person with preexisting
antibodies against the same HSV type [1]. Infections during
pregnancy may be transmitted to newborns: HSV-1 and
HSV-2 may cause eye or skin lesions, meningoencephalitis,
disseminated infections, or foetal malformations.
2. Epidemiology
In recent years, genital herpes has become an increasing
common sexually transmitted infection. From the late 1970s,
HSV-2 seroprevalence has increased by 30%, resulting that
one out of ﬁve adults is infected [4, 5].
HSV seroprevalence in patients with STD varies from
17% to 40% (6% in the general population and 14% in
pregnant women) [6, 7].
Ageandsexareimportantriskfactorsassociatedwiththe
acquisition of genitalHSV-2 infection. In fact,the prevalence
of HSV infection rises with age, reaching the maximum
around 40 years [4]. This infection appears related to the
number of sexual partners, and regarding sex it is more fre-
q u e n ti nw o m e nt h a ni nm e n[ 8, 9].
In addition, ethnicity, poverty, cocaine abuse, earlier
onsetofsexualactivity,sexualbehavior,andbacterialvagino-
sis can facilitate a woman’s risk of infection before pregnancy
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Regarding pregnant population, there is a high preva-
lence of genital herpes. Among Italian pregnant women, the
seroprevalence varies from 7.6% to 8.4% seroprevalence [9].
Nevertheless it is lower than that reported among pregnant
women in other countries. For example, in US, approxi-
mately 22% of pregnant women are infected with HSV-2,
and 2% of women acquire genital herpes during pregnancy,
placing their newborn at risk for herpes infection. In Italy,
the number of women who acquire HSV infection during
pregnancy is about 3%. The acquisition of genital herpes
during pregnancy has been associated with spontaneous
abortion, intrauterine growth retardation, preterm labour,
and congenital and neonatal herpes infections [12–14].
The risk of neonatal infection varies from 30% to
50% for HSV infections that onset in late pregnancy (last
trimester), whereasearly pregnancy infection carries a risk of
about 1%. When primary HSV infection occurs during late
pregnancy, there is not adequate time to develop antibodies
needed to suppress viral replication before labour. About
85%ofperinataltransmissionoccursduringtheintrapartum
period while transmission of HSV from mother to foetus
during pregnancy is less common. Moreover, studies in HIV-
infected pregnant women show that coinfection with HSV
increases signiﬁcantly the risk of perinatal HIV transmission
above all in women who had a clinical diagnosis of genital
herpes during pregnancy [15–17].
The newborn could be also infected by HSV-1, that may
represent almost one-third of all new genital HSV diagnoses.
3.Diagnosis
Primary symptomatic genital herpes, that occurs after an
incubation of a period of 2–20days, lasts up to 21 days
[4, 18]. Within women it causes blistering and ulceration
of the external genitalia and cervix leading to vulval pain,
dysuria, vaginal discharge, and local lymphadenopathy [18].
Vesicular and ulcerative lesions of the internal thigh, but-
tocks, perineum or in perianal skin are also observed. Both
in man and in womanprimary infection may be complicated
by systemic symptoms such as fever, headache, myalgia (38%
in men, 68% in women), and occasional meningitis and by
autonomicneuropathyresultinginurinaryretention,mainly
in women [9, 11].
All suspected herpes virus infections should be con-
ﬁrmed through viral or serological testing. A diagnosis of
genital herpes based on the clinical presentation alone has a
sensitivity of 40% and speciﬁcity of 99% and a false-positive
rate of 20% [19].
The tests used to conﬁrm the presence of HSV infection
canbedividedintotwobasicgroups:(1)viraldetectiontech-
niques and (2) antibody detection techniques. Primary viral
DNA testing techniques are viral culture and HSV antigen
detection by polymerase chain reaction (PCR). The antibody
detection techniques include the use of both laboratory-
based and point-of-care serologic tests to detect the presence
of antibodies to either HSV-1 or HSV-2. With viral detection
techniques, negative results do not rule out the presence of
infection [20]. The diagnosis of HSV should be conﬁrmed
either serologically or with viral culture. Isolation of HSV
in cell culture is the preferred virologic test for patients
who seek medical treatment for genital ulcers or other
mucocutaneous lesions and allows diﬀerentiation of the type
of virus (HSV-1 versus HSV-2) [21]. The sensitivity of this
test is limited because of several issues related to sampling
and transportation of the specimen. Additionally, as the
lesions heal, they are less likely to be culture positive [21].
Thus, a positive genital culture provides conclusive evidence
of genital HSV infection; however, a negative result does not
exclude the presence of infection. Polymerase chain reaction
techniques involve the ampliﬁcation of particular sequences
of DNA or RNA before detection and can thus detect
evidence of viral DNA at low concentrations. In one very
largestudy,PCRresultswerethreetoﬁvetimesmorelikelyto
be positive than were cultures. Cultures were more likely to
be positive at increasing concentrations of virus. Polymerase
chain reaction techniques are commercially available and
can diﬀerentiate between HSV-1 and HSV-2. Polymerase
chainreactionprovidesincreasedsensitivity overcultureand
may ultimately replace culture as the standard of care for
diagnosis [22].
At the ﬁrst prenatal visit also the partner history should
be investigated. In case of positive history in the male
partner, he should be strongly advised to have no oral and
sexual intercourse at the time of recurrence in order to
avoid infection (in particular during the third trimester of
gestation). Moreover, use of condoms throughout pregnancy
should be recommended to minimize the risk of viral
acquisition, although the male partner has no active lesions
[23].
4. Congenital andNeonatal Infection
Itisnecessarytodistinguishbetweencongenitalinfectionand
neonatal infection with HSV. In fact, HSV infection of the
newborn can be acquired during pregnancy, intrapartum
and postnatally. The mother is the most common source
of infection for the ﬁrst two routes of viral transmission.
Congenital infection is very rare due to the acquisition of the
virus in utero; it comes to the neonatal HSV infection when
the appearances of the lesions are more than 48 hours after
birth [24, 25].
Intrauterine HSV infection accounts for 5% of HSV
infections in neonates. The highest risk of intrauterine in-
fection has been observed in pregnant (about 50%) who
develop disseminated HSV infections and 90% of those are
related to HSV-2. Both primary and recurrent maternal
infectioncanresultincongenitaldisease,eveniftheriskafter
recurrent infection is small.
Intrauterine viral transmission is highest during the ﬁrst
20weeks of gestation leading to abortion, stillbirth, and
congenital anomalies. The perinatal mortality is 50% [24].
In 85–90% of neonatal HSV infections, HSV is acquired
at the time of delivery and 5–10% are caused by early post-
natal viral acquisition. A percentage of 70–85% of neonatal
HSV infections are caused by HSV-2, whereas the remaining
cases are due to HSV-1. The HSV-2 infection carries a graver
prognosis than that caused by HSV-1 [26].Infectious Diseases in Obstetrics and Gynecology 3
Thediseasetransmissiontothenewbornisdependenton
the type of maternal genital infection at the time of delivery.
I nf a c t ,n e o n a t a lh e r p e si sm u c hm o r ef r e q u e n t( 5 0 % )
in babies from mothers with a primary HSV infection with
respect to babies from mothers with recurrent HSV infection
(<3%).However,mostneonatalHSVinfections(about70%)
result from exposure to asymptomatic genital HSV infection
in the mother near delivery [27].
The prolonged rupture of membranes is a risk factor for
acquisition of neonatal infection [28]. Congenital intrauter-
ine infection is characterized by skin vesicles or scarring, eye
lesions (chorioretinitis, microphthalmia, and cataract), neu-
rologic damage (intracranial calciﬁcations, microcephaly,
seizures, and encephalomalacia), growth retardation, and
psychomotor development. Infants infected intrapartum or
postnatally by HSV can be divided into three major cate-
gories:
(1) HSV disease localized to the skin, eye, and/or mouth
(SEM); this syndrome is associated with a low mor-
tality but it has a signiﬁcant morbidity, and it may
progress to encephalitis or disseminated disease if left
untreated;
(2) HSV encephalitis with or without skin, eye, and/or
mouth involvement which causes neurologic mor-
bidity among the majority of survivors;
(3) disseminated HSV which manifests as severe multi-
organdysfunction(includingcentralnervoussystem,
liver, lung, brain, adrenals, skin, eye, and/or mouth)
and has a mortality risk that exceeds 80% in absence
of therapy [27, 28].
At diagnosis, symptoms are found with the following
frequency: skin vesicles 68%, fever 39%, lethargy 38%, sei-
zures 27%, conjunctivitis 19%, pneumonia 13%, and dis-
seminated intravascular coagulation 11%. Symptoms may
occasionally be present at birth, but occur in 60% later than
5days after birth and sometimes are present after 4–6weeks
of life [21].
Localized infections have been found in 50% of the
aﬀected neonates, involvement of the central nervous system
(CNS) in 33%, and disseminated infections in 17% of
the cases [19, 23]. Several studies have demonstrated that
disseminated HSV infections are characterized mainly by
liver and adrenals failure associated with shock symptoms
and disseminated intravascular coagulopathy [29–31]. Other
symptomsofHSVdisseminatedinfectionincludeirritability,
seizures, respiratory distress, jaundice, and frequently the
characteristic vesicular exanthem that is often considered
pathognomonic for infection. However, over 20% of infants
with disseminated infection do not develop skin vesicles
during the course of their illness. Encephalitis appears to be
a common component of this infection form, occurring in
about 60–75% of infants with disseminated HSV infection.
Mortality in the absence of therapy exceeds 80% [29].
The prognosis of infants with disseminated HSV disease
or neurological manifestations is poor. The mortality in
cases with neurological involvement by about 5% with 50%
of children with neurological sequelae, while in cases with
multiorganinvolvementmortality,is30%andthepercentage
of sequelae of 20% [28, 32].
5. Management of FirstInfection with
HSVinPregnancy
In 2008, the Society of Obstetricians and Gynaecologists of
Canada published guidelines on the management of HSV in
pregnancy [33].
The risk of infection to the infant appears to be higher
when the ﬁrst infection occurs during the third trimester of
pregnancy. In this case there may not be suﬃcient time for
the development of maternal IgG and their passage to the
fetus, and the risk of neonatal infection is 30 to 50% [34].
If infection occurs in the ﬁrst trimester of pregnancy, this
seems to be linked to an increase in spontaneous abortions
andcasesofintrauterinefetalgrowthrestriction.Onlyinrare
cases there is the transmission of the virus transplacentally,
resulting in a very severe congenital infection that can occur
with microcephaly, hepatosplenomegaly, intrauterine fetal
death, and IUGR. The use of antivirals is also permitted in
the ﬁrst trimester of pregnancy if the mother’s injuries are
particularly serious. At the moment there are enough data to
deﬁne dell’acyclovir safe to use during pregnancy [35].
When primary infection is acquired during the ﬁrst
t w ot r i m e s t e r so fp r e g n a n c y ,i ti sa d v i s a b l et oc a r r yo u t
sequentialviralculturesongenitalsecretionsfrom32thweek
of gestation [36]. Both viral culture that the nucleic acid
ampliﬁcation tests (NAATs) are considered as a test of choice
for symptomatic patients. As in Western Europe and the
United States, there are no comprehensively validated and
approved commercial NAATs available for detection of HSV
in many eastern European countries. However, some NAATs
for HSV detection have been developed and are available in
Eastern Europe, but have not been validated against their
internationally acknowledged analogues.
However, if two consecutive cultures result negative and
there are no active herpetic genital lesions at the time of
delivery, it is possible to perform a vaginal delivery. If ser-
oconversion is completed at the time of delivery, caesarean
section is not required since the risk of HSV transmission
to the foetus is low, and the neonate should be protected by
maternal antibodies.
If primary genital infection is acquired during the third
trimester of pregnancy, the optimal way of proceeding is not
well deﬁned. Most guidelines propose caesarean section for
women developing a primary clinical infection within the
last 4–6weeks of gestation, because they cannot complete
their seroconversion prior to the time of delivery, and
therefore they could infect the neonates. When vaginal
delivery is irreversible, since the risk of vertical transmission
is high (41%), a maternal and neonatal intravenous acyclovir
therapy is recommended [37–39].
6. Management of Infection Recurrent
HSVinPregnancy.
A pregnant woman with HSV lesion that has already
presented a ﬁrst infection in the past has circulating IgG,4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Recommended doses of antiviral medications for herpes in pregnancy [20].
First episode Recurrent episodes
Pregnancy Antiviral drug Recommended daily
dosage
Length of






Acyclovir Orally: 5 ×200mg 10 days Acyclovir Orally: 5 ×200mg 5days
Valacyclovir Orally: 2 ×500mg 10 days Valacyclovir Orally: 2 ×500mg 5days
Suppressive
treatment
Acyclovir Orally: 3 ×400mg Acyclovir Orally: 3 ×400mg
Valacyclovir Orally: 2 ×250mg From week 36
until delivery Valacyclovir Orally: 2 ×250mg From week 36
until delivery
whicharethenabletopasstheplacentaandreachthefetus.It
is so unusual that the fetus develops the infection with HSV.
If the lesion is present in genital skin during delivery, the risk
of infection for the baby will be 2–5% [28].
Instead, a woman with periodic reactivations of the virus
and asymptomatic at birth has a low risk (1%) to eliminate
the virus with vaginal secretions, so the risk of fetal infection
is even lower (0.02–0.05%) [28].
Randomized trials showed that the use of antiviral
drugs from the 36th week of pregnancy reduces the risk
of spreading of the virus in the absence of clinically visible
lesions and the risk of viral reactivation with decreased
percentage of caesarean sections [21].
The use of antiviral drugs is allowed before the 36th week
in case of very serious events in the mother, or if there is an
increased risk of preterm delivery.
The therapy includes the administration of acyclovir
400mg tablets 3 times daily or acyclovir 200mg tablets 4
times a day from week 36 until delivery, and viral cultures on
cervical-vaginal secretions from 36th week of gestation are
required. Recent studies also suggest the use of valacyclovir
at a dose of 200mg 2 times a day.
Inabsenceofclinicalherpeslesionsbutwithpositiveviral
cultures at delivery, caesarean section is recommended. On
the contrary, if all viral cultures are negative, in the absence
of clinical lesions, a spontaneous delivery is indicated.
Finally, in presence of clinical genital HSV lesions at the
onsetofdelivery,ifitmaybeassumedthatthefoetallungsare
mature, a caesarean section should be performed as quickly
as possible within 4–6 hours after membranes rupture [20,
21, 34].
7. Therapy
Pregnant women with a ﬁrst clinical episode or a recurrence
may be treated with acyclovir or valacyclovir at the recom-
mended dosages (Table 1). Since acyclovir and valacyclovir
are not oﬃcially approved for treatment of pregnant women,
patients should be informed to give consent before the
administration [20]. However, no increase of foetal abnor-
malities was ascribed to these treatments, although long-
term outcomes were not evaluated [20].
Treatment with acyclovir and valacyclovir by 36weeks of
pregnancy to term reduces the frequency of clinical manifes-
tations,verticaltransmission,eliminationofthevirusduring
birth by reducing the percentage of caesarean (Table 1)[ 28].
8. Conclusions
Genital herpes is a preventable chronic disease. Although
most HSV infections are subclinical, clinical disease can be
associated with substantial physical and psychosocial mor-
bidity. The clinical manifestations are diverse; hence a sus-
pected diagnosis of HSV should be conﬁrmed by laboratory
tests. The management of genital herpes should be tailored
to the individual and should include counselling about the
variable natural history appearance of lesions, education
about prevention of transmission, the link between HSV and
HIV, and discussion to assess the psychosexual eﬀects of
the disease. Antiviral therapy is safe and eﬀective, both for
episodic treatment and chronic suppression of HSV.
A large amount of information on the transmission of
herpes from male to pregnant partner, on the mode of trans-
mission from mother to newborn, mainly by maternal ﬁrst-
time infection in the third trimester of pregnancy, has been
published in literature.
Since the increasing prevalence of genital HSV infection
and apparent increase in the incidence of neonatal herpes,
we have focused our attention on prevention of maternal
foetal transmission as well as on the management of infected
pregnant women and neonate. Further studies are needed
to monitor the changing HSV-1 and HSV-2 trends and to
develop eﬀective strategies to prevent HSV infection. Finally,
the major vaccine strategies under development should take
in to account the three important features of herpesviruses:
the viral latency, the herpes immune escape, and the high
seroprevalence.
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